Estraderm MX Patches

Hormones Through the Skin: A Different Kind of HRT

Estraderm MX Patches are a transdermal hormone replacement therapy (HRT) that delivers oestradiol, the body's primary oestrogen, directly through the skin and into the bloodstream. Available in four strengths, 25 mcg, 50 mcg, 75 mcg, and 100 mcg, each patch is worn continuously on the skin and changed twice weekly. This delivery route bypasses the digestive system entirely, offering a clinically distinct approach to managing the symptoms of menopause.

For many women, the question is not simply whether to use HRT, but which form of HRT suits their body, lifestyle, and medical history most closely. Estraderm MX represents the transdermal route, a method of continuous oestrogen delivery through the skin that has been used in clinical practice for decades and is supported by current NICE guidance as a safe and effective option for the menopause.

This page provides factual clinical information about Estraderm MX to help you prepare for a conversation with a prescriber. A clinical consultation remains the necessary first step before any HRT can be prescribed.

Estraderm MX is a reservoir-type transdermal patch. Each patch consists of a transparent, flexible backing layer, a drug reservoir containing oestradiol in an alcohol gel, and an adhesive membrane that controls the rate at which oestradiol passes through the skin. When the patch is applied, oestradiol diffuses through the membrane and skin layers into the capillary network beneath, entering the systemic circulation directly.

This mechanism distinguishes Estraderm MX from oral oestrogen tablets. Tablets are absorbed through the gut and pass through the liver before reaching the circulation, a process known as first-pass hepatic metabolism that can influence clotting factor production and triglyceride levels. Transdermal patches bypass this process entirely, which is why current guidance suggests patches may carry a lower venous thromboembolism risk than oral HRT for appropriate patients.

Estraderm MX contains oestradiol as its sole active ingredient. It does not contain a progestogen. Women who still have their uterus will therefore need to use a separate progestogen alongside Estraderm MX to protect the womb lining from the effects of unopposed oestrogen. Women who have had a hysterectomy may use oestrogen-only therapy without this addition.

The appeal of transdermal oestrogen delivery lies in its consistency. Oral oestrogen tablets produce peaks in blood oestradiol levels shortly after ingestion, followed by a gradual decline before the next dose. Transdermal patches such as Estraderm MX release oestradiol at a relatively controlled rate throughout the wearing period, producing a steadier serum oestradiol level across the day.

That steady-state delivery matters clinically. Vasomotor symptoms such as hot flushes and night sweats are in part triggered by fluctuations in oestrogen levels. A more consistent hormonal environment, sustained by continuous transdermal delivery, can help reduce the frequency and severity of these episodes. Sleep quality, mood stability, and urogenital health may all respond to restored and stable oestrogen signalling.

Oestradiol from Estraderm MX also reaches bone tissue, where it suppresses osteoclast activity, the cellular process responsible for breaking down bone. After the menopause, the loss of oestrogen accelerates bone resorption, increasing the risk of osteoporosis and fracture. Maintained oestrogen levels can slow this process, which underpins the licensed indication for Estraderm MX in osteoporosis prevention.

The avoidance of first-pass hepatic metabolism is the key pharmacokinetic distinction of the transdermal route. Because the liver does not process transdermal oestradiol in the same way it processes oral oestradiol, the elevation of clotting proteins and inflammatory markers associated with oral oestrogen does not occur to the same degree. This has clinical relevance for women with certain cardiovascular or thrombotic risk factors, though individual assessment by a prescriber remains essential.

Choosing the Right Skin Site

Apply Estraderm MX to clean, dry, intact skin on the lower abdomen or upper buttock area. Avoid broken, irritated, or recently shaved skin. Do not apply patches to the breasts or near the waist, where clothing waistbands may rub and dislodge the patch. Rotate the application site with each patch change, leaving at least one week before returning to the same area of skin. Rotation reduces the risk of localised skin reactions.

How to Apply the Patch

Tear open the pouch carefully and peel away one half of the protective backing. Press the sticky side firmly to the chosen skin site, then fold back the second half of the backing and smooth the patch flat against your skin. Hold it in place for around 30 seconds with your palm. Check the edges are sealed. The patch should be comfortable and invisible under clothing.

Estraderm MX patches are designed to remain in place during bathing, showering, and swimming, although prolonged soaking in very hot water may loosen the adhesive. If a patch falls off before the change day, apply a new patch to a different skin site and continue to follow the same twice-weekly schedule.

Patch Change Schedule

Change your Estraderm MX patch twice weekly, every three to four days, at approximately the same time. A regular schedule, such as every Monday and Thursday morning, helps maintain consistent oestradiol levels. Remove the used patch before applying the new one. Fold the used patch in half, sticky sides together, and dispose of it in household waste. Do not flush patches down the toilet, as oestradiol residue can enter the water supply.

If You Forget to Change Your Patch

If you miss a patch change by a day or so, change the patch as soon as you remember and resume your twice-weekly schedule from that point. Do not apply two patches at once to compensate. Brief interruptions may cause a temporary return of symptoms, particularly flushes, but are not harmful.

Estraderm MX is available in four nominal release strengths, each describing the approximate quantity of oestradiol delivered through the skin over 24 hours. The table below summarises the range:

Starting Dose

Current guidance supports starting with the lowest dose that provides adequate symptom relief. For most women, the 50 mcg patch is the conventional starting point, though the 25 mcg patch may be considered as an initial dose in women who are particularly sensitive to hormonal changes or who have been oestrogen-depleted for an extended period. Your prescriber will advise on the appropriate starting strength based on your clinical history, symptom severity, and any relevant risk factors.

Dose Adjustment

After an initial review period, typically around three months, your prescriber will assess your response to treatment. If symptoms remain poorly controlled at 50 mcg, a step up to 75 mcg or 100 mcg may be considered. Conversely, if you are experiencing unwanted oestrogenic effects such as breast tenderness or bloating, a reduction to the 25 mcg patch may improve tolerability. These adjustments are made on an individual clinical basis.

Adding Progestogen

If you have a uterus, your prescriber will prescribe a progestogen alongside Estraderm MX. This may be as a separate oral tablet taken cyclically or continuously, as a progestogen-releasing intrauterine device, or as a combined patch from a different product. The choice depends on your clinical circumstances and preferences.

Skin and Application Site Effects

Because Estraderm MX is applied to the skin, local reactions at the patch site are the most distinctive side effects of this formulation and do not occur with oral HRT. These include:

1. Redness, itching, or mild irritation at the patch site, usually resolving within a day of patch removal
2. Persistent skin discolouration at the application site
3. Contact dermatitis, a more pronounced inflammatory skin reaction

Regular site rotation significantly reduces the risk of persistent local skin reactions. If you develop severe or spreading skin inflammation, or if reactions do not settle, speak to your prescriber.

Systemic Effects Common to Oestrogen Therapy

Effects related to oestrogen activity can occur with any form of HRT and may include:

1. Breast tenderness or fullness
2. Nausea or abdominal discomfort
3. Headache or migraine
4. Mood change or irritability
5. Fluid retention
6. Leg cramps
7. Irregular or breakthrough bleeding if progestogen is also taken and the regimen is sequential

Many of these effects are most noticeable in the first six to twelve weeks of treatment and tend to settle as the body adjusts.

Serious Effects That Need Urgent Attention

Seek immediate medical assistance if you experience:

1. Sudden chest pain or difficulty breathing, suggesting pulmonary embolism
2. Swelling, warmth, or pain in one leg, suggesting deep vein thrombosis
3. Sudden severe headache, vision disturbance, or facial or limb weakness, suggesting stroke
4. Jaundice or right upper abdominal pain suggesting liver involvement
5. A new breast lump or unexplained vaginal bleeding

Longer-Term Risk Profile for Transdermal Oestrogen

The breast cancer risk associated with oestrogen-only HRT differs from that of combined HRT. Evidence from the Collaborative Group on Hormonal Factors in Breast Cancer (Lancet, 2019) indicates that oestrogen-only therapy carries a smaller elevation in breast cancer risk than combined preparations. Transdermal oestrogen does not appear to carry the same increase in venous thromboembolism risk associated with oral oestrogen, based on current observational evidence. Your prescriber will assess your individual risk profile at consultation and review.

Licensed Indications

Estraderm MX is licensed in the UK for:

1. Relief of symptoms associated with oestrogen deficiency at the menopause, including natural menopause, premature ovarian insufficiency, and surgical menopause
2. Prevention of osteoporosis in postmenopausal women at increased risk of fracture where other treatments are not suitable

Who This Treatment Is Particularly Suited To

Transdermal HRT is an especially relevant option for women who:

1. Have elevated cardiovascular or thrombotic risk factors where the lower VTE profile of transdermal oestrogen is clinically advantageous
2. Experience nausea or gastrointestinal side effects with oral oestrogen tablets
3. Prefer a non-oral route that does not depend on daily tablet-taking
4. Have had a hysterectomy and require oestrogen-only therapy
5. Have hepatic conditions where first-pass liver metabolism of oral oestrogen is a clinical concern

Absolute Contraindications

Estraderm MX must not be used in women who have, or have had:

1. Known, suspected, or previous breast cancer
2. Known or suspected oestrogen-sensitive malignancies, including endometrial cancer
3. Undiagnosed, unexplained vaginal bleeding
4. Active or previous venous thromboembolism (deep vein thrombosis, pulmonary embolism)
5. Known thrombophilic disorders such as protein C, protein S, or antithrombin deficiency
6. Active or recent arterial thromboembolic disease including myocardial infarction, unstable angina, or stroke
7. Active liver disease where liver function has not normalised
8. Porphyria cutanea tarda
9. Known hypersensitivity to oestradiol or any patch component, including the adhesive

Clinical Caution Required

Prescribers exercise particular caution, and may recommend more frequent monitoring, in women with hypertension, diabetes, gallbladder disease, migraine with aura, a family history of breast cancer, endometriosis, systemic lupus erythematosus, or severe obesity. A thorough medical disclosure at consultation is essential to support safe prescribing.

Obtaining a prescription for Estraderm MX begins with a clinical consultation. The consultation is the primary clinical event in this process, not a gateway or a formality. A registered prescriber gathers detailed information about your symptoms, medical and family history, current medicines, and relevant lifestyle factors. The prescription is one possible outcome of that assessment, not a guaranteed result.

At Pharmacy Planet, your consultation is completed online and reviewed by a qualified prescriber. Because Estraderm MX is an oestrogen-only patch, the prescriber will need to establish whether you have had a hysterectomy, or whether the use of oestrogen without concurrent progestogen is clinically justified in your specific circumstances. If you have a uterus, the prescriber will also determine the most appropriate progestogen regimen to accompany the patch.

If the clinical information provided is insufficient to support a safe prescribing decision, the prescriber will request further information or recommend that you attend a face-to-face appointment. This may include a blood pressure check, measurement of weight and height, or a review of recent investigations such as a mammogram or bone density scan. These steps exist to protect you, not to create barriers.

Women prescribed Estraderm MX for the first time will typically be asked to return for clinical review after approximately three months. At that point, the prescriber will assess whether the starting dose is providing adequate symptom control, whether side effects have emerged, and whether any adjustment to the regimen is needed. Ongoing annual reviews allow the prescriber to continually reassess whether treatment remains appropriate and proportionate.

Store Estraderm MX patches below 25°C. Do not refrigerate patches, as low temperatures can affect the adhesive properties of the membrane and the integrity of the reservoir. Keep patches in their sealed pouches until the moment of use. Exposure to heat, direct sunlight, or humidity can degrade the oestradiol reservoir, so bathroom storage is not recommended.

Keep all patches in their original carton and out of the sight and reach of children. Even a used patch contains residual oestradiol that poses a risk if handled by a child. Used patches should be folded in half, sticky sides facing inward, and placed in household waste. Do not flush patches down the toilet or place them in recycling streams. Oestradiol contamination of waterways is an environmental concern associated with improper patch disposal. Unused or expired patches should be returned to your pharmacy.

Choosing the right HRT is a clinical decision, not a one-size-fits-all choice. Delivery route, oestrogen type, progestogen class, and bleed preference all shape which preparation is most appropriate for any individual woman. The tables below group products by formulation type so that like is compared with like, helping you understand how each option differs from others in its class before you speak with a prescriber.

Transdermal Patches

The table below compares commonly prescribed HRT patches. All patches deliver oestradiol transdermally, bypassing hepatic first-pass metabolism, and are associated with a lower venous thromboembolism risk than oral preparations.

Pharmacy Planet operates as a GPhC-registered online pharmacy under the supervision of a qualified superintendent pharmacist. Our prescribers are registered healthcare professionals who approach each consultation as a clinical responsibility, not a transactional exchange. We do not issue prescriptions on the basis of questionnaire responses alone where additional clinical information is needed to prescribe safely.

For transdermal HRT specifically, our prescribers are aware of the nuanced clinical considerations that distinguish patch-based oestrogen delivery from oral alternatives. These include the significance of the first-pass effect, the implications of the route of administration for women with specific risk factors, and the importance of correct patch application and disposal. Our consultation process is designed to surface that clinical detail in a way that is accessible, confidential, and thorough.

If you would like to find out whether Estraderm MX may be clinically appropriate for your situation, you are welcome to begin a consultation using the link on this page. There is no obligation to proceed, and you will receive a considered clinical response to your submission.

1. Estraderm MX Patches – Summary of Product Characteristics (SmPC). Novartis Pharmaceuticals UK Ltd. Available at: www.medicines.org.uk/emc. Accessed June 2025.
2. NHS. Hormone replacement therapy (HRT). Available at: www.nhs.uk/conditions/hormone-replacement-therapy-hrt. Accessed June 2025.
3. NICE. Menopause: diagnosis and management. NG23. Updated December 2019. Available at: www.nice.org.uk/guidance/ng23. Accessed June 2025.
4. British National Formulary (BNF). Estradiol (oestradiol). Available at: bnf.nice.org.uk. Accessed June 2025.
5. MHRA. Hormone-replacement therapy: updated advice. Drug Safety Update vol 12 issue 11, June 2019. Available at: www.gov.uk/drug-safety-update. Accessed June 2025.
6. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk. Lancet 2019; 394(10204):1159–1168.
7. Vinogradova Y et al. Use of hormone replacement therapy and risk of venous thromboembolism. BMJ 2019; 364:k4810.
8. British Menopause Society. Transdermal HRT and thromboembolism. Available at: thebms.org.uk. Accessed June 2025.